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Costa et al. recently reported that racial disparities prevented nearly 40% of non-Hispanic blacks with multiple
myeloma (MM) from undergoing stem cell transplantation (SCT), but the authors were unable to provide an
explanation for the disparities because of limitations of their datasets. They hypothesized that socioeconomic
status (SES) and/or insurance providers might account for the disparity. To examine the issue raised by Costa
et al., we performed a secondary analysis using hierarchical multivariate logistic regressionwith data previously
collected to determine if age at diagnosis, sex, SES, primary insurance provider at diagnosis, and comorbidity
score help explain the racial disparities in SCT utilization. A model of race, age, sex, SES, insurance provider, and
comorbidity score was the most accurate model in predicting stem cell utilization status (c2[12] ¼ 193.859; P <
.001; area under the curve ¼ .837; P < .001). After controlling for the covariates, black patients were less likely
to undergo SCT than white patients (adjusted odds ratio, .49; 95% conﬁdence interval, .27 to .89; P ¼ .013). In
conclusion, we also observed racial disparities between black and white patients with MM in SCT utilization
and these are not fully accounted for by the covariates age, sex, SES, insurance provider, and comorbidity score.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION secondary analysis on the dataset used in our previous study
Costa et al. recently reported on racial and ethnic
disparities in utilization of autologous stem cell trans-
plantation (SCT) for treatment of multiple myeloma (MM)
[1]. They found that racial disparities prevented nearly 40% of
non-Hispanic blacks from undergoing SCT.
We commend the authors for addressing this topic
and for their well-constructed study design, but unfortu-
nately they were unable to provide an explanation for the
disparities because of limitations of their datasets; they
hypothesized that socioeconomic status (SES) and/or insur-
ance provider might account for the disparity.
We recently reported on outcomes among 562 patients
diagnosed with MM from 2000 through 2009 at our insti-
tution [2]. Similar to Costa et al., we found that black patients
were less likely to undergo SCT than whites (45% versus 67%,
P < .001), but SCT utilization was not the focus of the article.
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ty for Blood and Marrow Transplantation.to determine if age at diagnosis, sex, SES, primary insurance
provider at diagnosis, and comorbidity score help explain the
racial disparities in SCT utilization.MATERIALS AND METHODS
We performed a secondary analysis using data previously collected. The
methodologies used for data collection are explained elsewhere [2].Statistical Analysis
All data was analyzed using IBM SPSS Statistics version 21. We used
standard descriptive statistics to describe the sample. We then developed a
model of stem cell transplantation utilization using hierarchical multivariate
logistic regression to test whether certain variables contributed signiﬁcantly
to explaining the outcome. In developing the model, we started with the
variables utilized by Costa et al. (race, age, and sex). Less than 1% of the
population was Hispanic, therefore, ethnicity was not included in the
analysis. We then added SES and insurance provider at time of diagnosis. In
the third and ﬁnal step, we added the comorbidity score. To determine
whether the additional variables improved the model we used the likeli-
hood ratio test and the change in area under the curve (AUC).RESULTS
Five hundred sixty-two patients were eligible for analysis.
Seventy-three percent of patients were white, 26% were
black; the median age at diagnosis was 59 years (range, 33 to
Figure 1. Receiver operating characteristic curve of 3 models predicting stem
cell transplantation utilization in multiple myeloma. The area under the curve
(AUC) improved from model 1 (race, age, and sex) to model 2 (race, age, sex,
SES, and insurance provider), and again from model 2 to model 3 (race, age,
sex, SES, insurance provider, and comorbidity score).
Table 1
Multivariate Analysis of Stem Cell Transplantation Utilization for Multiple
Myeloma
Factor aOR 95.0% CI for aOR P Value
Lower Upper
Race .013
White 1*
Black .49 .27 .86 .013
Other .22 .04 1.21 .082
Age (per year) .91 .88 .94 <.001
Sex
Female 1*
Male .59 .37 .95 .029
SES .088
High SES 1*
Middle SES .61 .32 1.15 .126
Low SES .53 .30 .94 .030
Insurance provider <.001
Private 1*
Medicare .40 .22 .74 .003
Medicaid .41 .14 1.25 .116
No insurance .16 .06 .43 <.001
Comorbidity score <.001
None 1*
Mild .85 .48 1.49 .564
Moderate .43 .22 .81 .009
Severe .18 .07 .47 <.001
* Reference category.
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tients underwent SCT (341 autologous and 2 syngeneic).
A multivariate logistic regression model of race, age, and
sex was signiﬁcantly better than the baseline at explaining
SCT utilization ([c2(4) ¼ 141.459; P < .001]; AUC ¼ .788; P <
.001). After adding SES and insurance provider at time of
diagnosis, the model improved ([c2(9) ¼ 174.699; P < .001];
AUC ¼ .822; P < .001). After comorbidity score was added in
the third and ﬁnal step, the model again improved (c2[12] ¼
193.859; P< .001]; AUC¼ .837; P< .001). Based on the results
of the likelihood ratio test and the change in AUC, each step
signiﬁcantly improved the model (P < .001). The full model
accurately predicted the SCT utilization status in 76% of the
patients; it was better at predicting SCT utilization (84% ac-
curacy) than it was at predicting no SCT utilization (64%);
therefore, it is more sensitive than speciﬁc. Figure 1 shows the
receiver operating characteristic curves of 3 models.
After controlling for age and sex, black patients were
less likely to undergo SCT than whites (adjusted odds ratio
[aOR], .30; 95% conﬁdence interval [CI], .19 to .50]; P < .001);
after adding SES and insurance provider at time of diagnosis
and later comorbidity score, there was no signiﬁcant change
in the disparity between black and white patients (aOR, .46;
95% CI, .26 to .80; P < .001; and aOR, .49; 95% CI, .27 to .89;
P ¼ .013, respectively). Results of the full multivariate model
are summarized in Table 1.DISCUSSION
Here we found that, as hypothesized by Costa et al., SES
and insurance provider were associated with SCT utilization,
but these factors did not account for the racial disparity
observed between blacks and whites. We also added co-
morbidity score, as it has been associated with an increased
risk of nonrelapse morbidity and mortality after SCT [3], and
therefore it is often used to determine eligibility for the
procedure; we found that it was too associated with SCT
utilization, but it did not account for the observed racial
disparity. Similar results have been reported [4]. Other
possible explanations for the racial disparity in SCT utiliza-
tion observed between blacks and whites might be patientand/or physician bias. In conclusion, we also observed racial
disparities between black andwhite patients withMM in SCT
utilization, and these are not fully accounted for by the
covariates age, sex, SES, insurance provider, and comorbidity
score.
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